Trial Profile

First in Human Phase I Study of 225Actinium-MTI-201 (225Ac-MTI-201) in Metastatic Uveal Melanoma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 17 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MTI 201 (Primary)
Indications Uveal melanoma
Focus Adverse reactions; First in man
Sponsors Modulation Therapeutics

Most Recent Events

13 Mar 2025 Planned primary completion date changed from 25 Apr 2025 to 31 Mar 2026.
04 Jun 2024 Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
11 Mar 2024 Planned primary completion date changed from 25 Dec 2023 to 25 Apr 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com